Glucose metabolism is increased in most aggressive tumors and it is commonly evaluated by positron emission tomography-computed tomography (PET-CT) with 18F-fluorodeoxyglucose ([18F]FDG), measuring the Maximum Standardized Uptake Value (SUVmax) for the assessment. Particularly, it is known that breast cancer expresses different glucose metabolism inrelation to estrogen receptor (ER), progesterone receptor (PR), Ki67 score, tumor grading, tumor size, and Human Epidermal Growth Factor Receptor 2 (HER2). We present an interesting case of a woman with two different, synchronous breast cancers characterized by different glucose metabolism, according to literature knowledge.
Keywords: Breast cancer; PET; [18F]FDG; glucose metabolism; histotype.